Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

JCO Precis Oncol. 2022 Oct:6:e2200353. doi: 10.1200/PO.22.00353.

Authors

Juan Alban¹, Adam DuVall², Sandeep Gurbuxani³, Wendy Stock², Anand Ashwin Patel²

Affiliations

¹ Department of Medicine, University of Chicago, Chicago, IL.
² Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.
³ Section of Hematopathology, Department of Pathology, University of Chicago, Chicago, IL.

No abstract available

MeSH terms

Humans
Inotuzumab Ozogamicin
Lymphoma, B-Cell*
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Retreatment

Substances

Inotuzumab Ozogamicin